Proteomics International Laboratories Ltd today announces that its collaborative study with Janssen Research & Development, LLC has found a significant reduction in the PromarkerD risk scores of patients with type 2 diabetes taking canagliflozin, an SGLT2-inhibitor diabetes drug.
Results to be presented at the Australasian Diabetes Congress from 11-13 August 2021.
